Single Peptides · Exact presentation
CJC-1295 DAC · 2 mg Vial
CJC-1295 DAC · 2 mg Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.
Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.
Dosing & Reconstitution Guide
For a 2 mg presentation, the reference concentration of 2 mg/mL mathematically corresponds to 1 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 2 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.02 mg at this concentration.
Standard Weekly Approach (1 mL = 2.0 mg/mL)
The source chart summarizes “2 mg” at “Weekly” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Standard Weekly Approach (1 mL = 2.0 mg/mL)
| Week | Weekly Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–12 | 2,000 mcg (2 mg) | 100 units (1.00 mL) |
Reconstitution Steps
For a 2 mg presentation, the reference concentration of 2 mg/mL mathematically corresponds to 1 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 2 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.02 mg at this concentration.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]
Allow vials to reach room temperature before opening to reduce condensation uptake.
How This Works
It relates to the growth-hormone-releasing hormone, secretagogue receptor, and GH/IGF-1 axis. Each molecule acts at a different point and should not be treated as interchangeable.
Potential Benefits & Side Effects
GH/IGF-1 signaling is systemic and may carry metabolic, endocrine, and proliferative risks. No clinical regimen is provided here.
Source trail
Scientific references and source discovery
- PeptideDosages — exact CJC-1295 DAC · 2 mg Vial entrysecondary-structure
- PubMed — literature search for CJC-1295 DACprimary-discovery
- ClinicalTrials.gov — study search for CJC-1295 DACtrial-registry
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference